A simple and sensitive liquid chromatography/ tandem mass spectrometry (LC/MS/MS) method was developed and validated for the quantification of bulleyaconitine A (BLA) in human serum. Samples were extracted from human serum by protein precipitation. Domperidone was used as internal standard (I.S.). Chromatography separation was performed on a Waters Sunfire C18 column (2:1 Â 50 mm, 5 m) with a gradient mobile phase. Detection was performed in positive mode using multiple reaction monitoring (MRM) of the transition m=z 644:2 > 584:3 for BLA and m=z 426:3 > 175:3 for I.S. The proposed method was validated in a linear range of 0.0587-11.7 ng/ml. Intra-and inter-day precision was better than 9.88% and 7.76%. The recovery for BLA was 97.90%, and for I.S. 89.40%. This method provides a simple, rapid, specific, and sensitive tool for the quantitativedetermination of BLA in human serum, and can be used to monitor serum levels in patients treated with BLA.
Some Aconitum alkaloids, such as aconitine, are known aneurotoxins, and are highly toxic to humans and animals. 1) Aconite roots and their processed products are used as important ingredients in Chinese medical preparations for their anti-inflammatory, analgesic and cardiotronic effects.
2) Bulleyaconitine A (BLA, Fig. 1 ), a dister-diterpene type Aconitum alkaloid, is an active ingredient extracted from Aconitum bulleyanum plants that exhibits strong analgesic and anti-inflammatory properties in vivo. The use of purified BLA in solution or in tablets, as an analgesic agent for the treatment of chronic pain, rheumatoid arthritis, osteoarthritis, and periarthritis, remains common in China.
3) The analgesic effect of BLA was reported to be as much as 3, 65, and 7,200 times as potent as 3-acetylaconitine, morphine and aspirin respectively. 4) BLA is classified as a nonnarcotic analgesic, and its therapeutic action might be related to the brain 5-HT level and action on neuronal sodium channels, and no physical dependence has been observed in monkeys. 5) To date, BLA in injections (0.2 mg) and in tablets/soft-gel capsules (0.4 mg) has been introduced into clinical treatment in China. 5) However, the potential toxicity of BLA is severe. In animal studies, the LD 50 of BLA, injected subcutaneously, was 0.92 mg/kg for mouse and 0.51 mg/kg for rat.
3) BLA induced acute systemic side effects in rats, including sedation, respiratory distress, and ventricular arrhythmia when a large dose of BLA was injected. 5) Although no death case has been reported and the major side effects in clinical applications are nausea, numbness, palpitation and anaphylaxis, it may be necessary to monitor the serum concentration of BLA in patients to decrease the adverse drug reactions and optimize drug treatment.
Various methods have been reported for the determination of Aconitum alkaloids such as aconitine, mesaconitine, jesaconitine, hypaconitine, and deoxyaconitin in body fluids and food. [6] [7] [8] [9] [10] The techniques used include high-performance liquid chromatography (HPLC) with UV detection, 6) HPLC with mass spectrometry (MS) 7, 8) and gas chromatography (GC) with MS detection. 9, 10) But the blood concentration of BLA was extremely low because of the low dose and rapid metabolism of the drug. Therefore, it is necessary to develope a highly sensitive and specific method to determine BLA in blood. Liquid chromatography-tandem mass spectrometry (LC/MS/MS) is an attractive method that has markedly improved detection sensitivity for drugs, and quantification on the order of picograms, is becoming possible. Weng et al. 11) have reported a highly sensitive LC/MS/MS method to determine the plasma BLA concentration. Unfortunately, the method involves using a large volume of plasma and a laborious liquid-liquid extraction procedure. This lowers sample throughput, and it was decided to develop a sensitive method to simplify sample pretreatment and decrease sample volume without sensitivity loss. This paper describes the development and validation of a sensitive, specific, simple, and rapid LC/MS/MS method using a simple protein precipitation procedure for the quantification of BLA in human serum, allowing the assay of up to 100 samples per day.
Experimental
Materials and reagents. BLA (98.7%, batch 20071202) was kindly made available by Yunnan Haobang Pharmaceutical Co., Ltd.
y To whom correspondence should be addressed. Fax: +86-10-8226-6673; E-mail: suodizhai@yahoo.com.cn Abbreviations: BLA, bulleyaconitine A; I.S., internal standard; LC/MS/MS, liquid chromatography-tandem mass spectrometry; MRM, multiple reaction monitoring; QC, quality control; RSD, relative standard deviation (Yunnan, China), and the internal standard (I.S.) domperidone (Fig. 1) was obtained from the National Institute for the Control of Biological Products (Beijing, China). Methanol (Fisher, Richmond Hill, USA), acetonitrile (Fisher) and formic acid (Dikma, New Jersey, USA) were of HPLC-grade. The mobile phase was filtered with a 0.45 mm film before use. Drug-free human serum was purchased from a local blood bank (Beijing Red Cross Blood Center, Beijing, China) and stored at À40 C. The water used was deionized and distilled.
Instrumentation. The HPLC separation system consisted of Agilent 1200 series liquid chromatography (Agilent Technologies, Palo Alto, CA) including a heated column compartment. Mass spectrometric detection was performed using Agilent 6410 triple quadrupole mass spectrometry (Agilent Technologies) equipped with an electrospray ionization source. The HPLC and MS systems were run using MassHunter B.01.03 software.
Preparation of standard and quality-control samples. Two stock solutions of BLA (0.587 mg/ml), which were independently weighted, and one stock solution of I.S. (0.354 mg/ml) were prepared by dissolving a known weight of each in acetonitrile. One stock solution of BLA was used for spiking calibration standards and the other for quality control (QC) samples. Serial dilutions of these stock solutions were made to give a working solution of appropriate concentrations using acetonitrile. All the solutions were stored at 4 C and were brought to room temperature before use.
A 7-point standard curve ranging from 0.0587 to 11.7 ng/ml of BLA having calibration standards at 0.0587, 0.117, 0.586, 1.17, 2.93, 5.86, 11.7 ng/ml was prepared by spiking 190 ml of the blank serum with 10 ml of BLA working solutions. QC samples were prepared at four concentration levels: 0.164 ng/ml, low QC sample (LQC); 0.859 ng/ml, middle QC sample (MQC); and 9.45 ng/ml, high QC sample (HQC), in a manner similar to the calibration curve from the working solution. The calibration curves (Y ¼ aX þ b) were constructed by plotting the peak area ratios of BLA/I.S. (Y) vs. the corresponding analyte concentrations (X) in ng/ml, and the linearity was established by least-squares regression.
Sample preparation. A 200 ml aliquot of human serum sample was mixed with 10 ml of I.S. working solution (35.4 ng/ml of domperidone). The 600 ml of methanol was added, and the mixture was vortexmixed for 2 min. The sample was centrifuged at 16,000 rpm for 5 min. The supernatant was transferred into an HPLC vial, and a volume of 15 ml was injected into the LC/MS/MS system. Chromatography conditions. Chromatography separation was achieved after serum samples were injected onto a Waters Sunfire C 18 analytical column (50 Â 2:1 mm, 5 mm), maintained at a temperature of 35 C. Two separate mobile phases were used to construct the gradient at a flow rate of 0.3 ml/min, mobile phase A consisting of 0.1% formic acid in water and mobile phase B consisting of 0.1% formic acid in methanol. Isocratic elution of the analyte was achieved using a mixture of 80% of A and 20% of B at the beginning, then changed to 10% of A and 90% of B in a gradient step within 0.8 min lasting to 2.5 min, and finally the column was eluted with 80% of A and 20% of B for 6 min.
Mass spectrometry conditions. Electrospray ionization was performed in positive ion mode with nitrogen as the nebulizer and drying gas. Collision-induced dissociation was achieved using nitrogen as the collision gas. The ion source conditions were set as follows: gas temperature, 350 C; nebulizer gas, 30 psi; gas flow, 8 liters/min; capillary voltage, 1,500V; fragmentor, 140V for BLA and 150V for I.S.; collision energy, 40V for BLA and 28V for I.S., and dwell time 300 ms. BLA and I.S. were monitored in the multiple-reaction monitoring (MRM) mode using the following transitions: 644:2 > 584:3 (BLA) and 426:3 > 175:3 (I.S.).
Method validation. Selectivity and lower limit of quantification (LLOQ). Blank human serum was screened prior to spiking to ensure that it was free of endogenous interference at the retention times of BLA and I.S., and selectivity was performed by analyzing six blank serum samples from different donors. The LLOQ was determined as the lowest concentration of the calibration curve. The mean percentage deviation from the nominal concentration was 20% and the relative standard deviation (RSD%) was 20%.
Linearity. The linear equation was assessed by injecting the amounts of known standard samples (0.0587, 0.117, 0.586, 1.17, 2.93, 5.86, and 11.7 ng/ml) of BLA. A weighted linear regression was used to calculate the equation relating the peak area ratio between drug and IS and the concentration of the analyte. The calibration curve should show a correlation coefficient r 2 of 0.99 or better. Precision and accuracy. Intra-batch precision and accuracy were determined by analysis of five replicates at each QC level in three analytical runs. The performance of the assay was considered acceptable if the precision (RSD%) at each concentration was 15% for intra-batch and inter-batch variability, and the expected result was within 15% of the assigned concentration for both intra-and interbatch variability.
Recovery. Extraction recoveries from human serum were determined by comparison of the MS response from extracted samples containing known amounts of drugs (0.164, 0.859, and 9.45 ng/ml; IS 35.4 ng/ml).
Stability. Freeze-thaw stability was determined by comparing stability samples that had been frozen at À40
C and thawed at room temperature 3 times with a fresh spiked calibration standard. The stability of the spiked human serum stored at -40 C (long-term stability) was evaluated by analyzing LQC, MQC, and HQC samples that were stored for 21 d together with the freshly spiked calibration standard. The stability of the spiked human serum stored at ambient temperature was evaluated at 4 h. The processed sample stability was evaluated by comparing the extracts that were injected immediately with the samples that were re-injected after storage in the autosampler at an ambient temperature for 24 h.
Carryover. The Carryover effect was assessed by analyzing spiked serum samples at the upper limit of quantification (ULOQ) (11.7 ng/ml, n ¼ 5) followed by blank samples. To evaluate the matrix effect on the method, intraday assay was conducted with QC samples prepared from six different sources of serum samples.
Results and Discussion

Method development
The goal of this study was to develop and validate a simple, rapid, and sensitive assay method for the quantification of BLA. To achieve this goal, during method development different options were evaluated to optimize detection parameters, chromatography and sample extraction. Both the positive and the negative mode were investigated. BLA and I.S. gave the best responses in positive polarity due to their basic nature. To achieve the desired sensitivity, positive polarity was used for quantitation. Further, the pH of the mobile phase was kept acidic to produce a better signal since BLA and I.S. remain in the ionic form at acidic pH. Examples of the fragmentation patterns on the mass spectrum of BLA and I.S. are shown in Fig. 1 . The major precursor ions [ðM þ HÞ þ ] observed were m=z 644.2 for BLA and m=z 426.3 for I.S. A predominant and a specific fragment of BLA and I.S. were selected and used as the product ions to be monitored.
The increasing focus on high-throughput sample analysis has led to a common practice of preparing samples by the simplest, fastest method possible, which often means using simple one-step protein precipitation to reduce laborious extraction procedures like liquidliquid extraction (LLE) or solid-phase extraction (SPE), which involve drying and reconstitution, but to overcome the dilution of samples by the precipitation technique, chromatography was optimized to reduce ion suppres-sion and increase the signal. Several analytical columns including a Restek Ultra C18 (100 mm Â 2:1 mm, 5 mm), a Waters Xterra C18 (50 mm Â 2:1 mm, 5mm), an Agilent Zorbax SB C18 (30 mm Â 2:1 mm, 3.5 mm), and a Waters Sunfire C18 (50 mm Â 2:1 mm, 5 mm) were evaluated to yield sharp and symmetrical peaks. It was found that the Ultra C18 and Xterra C18 columns produced lower responses for this analyte, while the retention time of analyte on the Zorbax SB C18 column was shorter than the others. This might have been affected by matrix interference. Finally, the use of Waters Sunfire C18 column resulted in increased response and satisfying peak shapes. The column oven temperature was optimized at 35 C in order to obtain symmetry of analyte peaks. A gradient mobile phase consisting of 0.1% formic acid (A) and methanol (containing 0.1% formic acid, B) was found to produce adequate retention and good peak shapes for BLA and I.S. The isocratic elution from 0 to 2.5 min, described in ''Experimental'' above, was needed to elute the ingredients possessing an ion-suppression effect against BLA and I.S., and the target compounds, BLA and I.S., emerged at 3.45 and 3.30 min respectively. The resulting signal with optimized chromatography and detection parameters enabled the elimination of the laborious extraction steps of evaporation of eluent and reconstitution involved in generic SPE methods without compromising sensitivity, which further resulted in reduced processing time.
Selectivity
Representative chromatograms obtained from blank serum and serum spiked with LLOQ and LQC standards are presented in Figs. 2 and 3 . No interfering peaks from endogenous compounds were observed at the retention time of BLA or of I.S. when six blank serum extracts from different sources were analyzed. The predominant product ions, of m=z 584.2 and 175.3, were specific for BLA and I.S. respectively.
Linearity
The weighted regression (1/X) calibration was linear over a concentration range of 0.0587-11.7 ng/ml for BLA in human serum. The average equation of linearity was Y ¼ ð13:3933 AE 1:8553ÞX þ ð0:0014 AE 0:0004Þ (n ¼ 5), and each of the correlation coefficients (r 2 ) was greater than 0.9970.
Sensitivity
The LLOQ is defined as that concentration of BLA that can be determined with acceptable precision (RSD% < 20%) and accuracy (bias < 20%). It was found to be 0.0587 ng/ml. These data are tabulated in Table 1 for BLA. The intra-and inter-day precision of the LLOQ serum samples was 6.41% and 11.71% respectively. The intra-and inter-day accuracy of the LLOQ serum samples was 7.09% and 5.45% respectively.
Precision and accuracy
An assessment of intra-and inter-day precisions were conducted by analyzing the QC samples at three levels. The data on precision are presented in Table 1 . The intraday precision and accuracy (bias) ranged from 1.68% to 9.88% and À2:53% to 0.25% respectively. Inter-day precision and accuracy were determined by pooling all the individual assay results of replicate (n ¼ 5) QC samples over the three separate batch runs. The inter-day precision and accuracy (bias) were 4.47%-7.76% and À4:19%-0.42% respectively of the nominal value.
Recovery
Five replicate at low, medium, and high QC samples for BLA, were prepared for recovery determination. The mean values of the recovery rate for BLA and I.S. were 97.90 and 89.40 respectively.
Robustness
Matrix interference on ionization and detection is likely to be a problem when protein precipitation is the only step used for sample preparation as compared to the liquid-liquid extraction and solid-phase extraction methods. In spite of this, the protein precipitation method is employed as the routine sample preparation procedure for LC/MS/MS assays in our laboratory mainly, due to its simplicity and robustness. The matrix effect on ionization was assessed by spiking extracts from six independent sources of the control matrix at the LQC, MQC, and HQC levels. The peak areas of BLA had RSDs of 7.42%, 1.69% and 4.91%, and the peak area ratios of BLA/I.S. had RSDs of 6.26%, 7.08% and 3.93%. These results indicated that the matrix effect did not affect the relative efficiency of ionization of the BLA and I.S. (Table 2) . Although peaks at the retention times of BLA were observed in single injections of blank sample after one ULOQ calibration standard in the intraday and inter-day validation batches, all the peak areas observed were less than 20% of the LLOQ. This was deemed to be an anomalous result that had no impact on the integrity of the study.
Stability
Serum samples containing BLA can therefore be kept for up to 4 h at ambient temperature prior to processing. The stabilities of the BLA samples were investigated at the LQC, MQC, and HQC levels (n ¼ 3). The calculated concentrations and RSD% are listed in Table 3 . The average accuracy (bias) ranged from À3:61% to 3.23% after sample was placed at ambient temperature for 4 h. Extract stability in the autosampler was also determined. The value was between À11:53% to À3:66% after sample was placed in the autosampler at ambient temperature for 24 h. These data indicate that BLA were stable in the serum for at least 4 h at ambient temperature, and that the extracts were stable in the autosampler at ambinet temperature for 24 h.
Freeze-thaw stability was also examined in the experiment. The LQC, MQC, and HQC samples were subjected to freeze-thaw cycles consisting of a thaw to room temperature (more than 4 h), vortexing, and refreezing (À40 C) at least overnight. After each freeze-thaw cycle the samples were analyzed. The accuracy (bias) was between À9:55% and À6:72% after 3 cycles. These results indicate that the samples were stable after freeze-thaw cycles (Table 3 ). The long-term stability of BLA in the serum at À40
C was tested at the LQC, MQC, and HQC levels (n ¼ 3). The results ranged from À6:59%-2.55% (Table 3) . These results indicate that BLA was stable for at least 21 d. serum is needed for analysis by this method, which greatly facilitates the collection of samples. The method allows quantification of BLA over the range 0.0587-11.7 ng/ml. More than 100 samples could be analyzed in a day using this method. It can be used to monitor serum levels in patients treated with BLA, and it provides a practical tool for in vivo detection of BLA. 
